drugset / Trial / NCT00174928

A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease

NCT00174928

Phase 1 Completed 24 enrolled Takeda
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.

Timeline

Start
2005-05
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 0.5 mg/kg Oral
Subject Lansoprazole Other / unclassified 1 mg/kg Oral